These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8993501)

  • 41. Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
    Kanagasabai R; Liu S; Salama S; Yamasaki EF; Zhang L; Greenchurch KB; Snapka RM
    Biochemistry; 2009 Apr; 48(14):3176-85. PubMed ID: 19236054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
    Pommier Y
    Chem Rev; 2009 Jul; 109(7):2894-902. PubMed ID: 19476377
    [No Abstract]   [Full Text] [Related]  

  • 43. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
    Wu J; Yin MB; Hapke G; Tóth K; Rustum YM
    Mol Pharmacol; 2002 Apr; 61(4):742-8. PubMed ID: 11901212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage.
    Mei C; Lei L; Tan LM; Xu XJ; He BM; Luo C; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
    Biomed Pharmacother; 2020 May; 125():109875. PubMed ID: 32036211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topological nuts and bolts.
    Nash HA
    Science; 1998 Mar; 279(5356):1490-1. PubMed ID: 9508726
    [No Abstract]   [Full Text] [Related]  

  • 50. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
    Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.
    Vladu B; Woynarowski JM; Manikumar G; Wani MC; Wall ME; Von Hoff DD; Wadkins RM
    Mol Pharmacol; 2000 Feb; 57(2):243-51. PubMed ID: 10648633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
    Okada K; Andoh T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1562-7. PubMed ID: 1651683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
    Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA topoisomerase I poisons.
    Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
    Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
    [No Abstract]   [Full Text] [Related]  

  • 56. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
    Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
    Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.
    Roy A; Tesauro C; Frøhlich R; Hede MS; Nielsen MJ; Kjeldsen E; Bonven B; Stougaard M; Gromova I; Knudsen BR
    PLoS One; 2014; 9(6):e99628. PubMed ID: 24960044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are there any better camptothecins than the ones we have?
    Takimoto CH
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):578-9, 600. PubMed ID: 16258452
    [No Abstract]   [Full Text] [Related]  

  • 60. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
    Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
    Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.